Read ePaper

Covishield

“Safety is primary focus for all our vaccines”: Covaxin-Developer Bharat Biotech Amid Reports on AstraZeneca Vaccine

02 May 2024

Amidst concerns about potential rare side effects linked to the AstraZeneca-Oxford COVID-19 vaccine, Bharat Biotech, the creator of Covaxin, emphasized in a statement their unwavering dedication to prioritizing safety above all else in the development of their vaccine. They underscored that Covaxin was the exclusive COVID-19 vaccine in India's government...

DGCI Approves Covovax In Markets

17 Jan 2023

The Drugs Controller General of India (DCGI) has approved the official market business of Serum Institute of India's (SII) COVID-19 vaccine Covovax as a tertiary booster dose.This vaccine can be taken as a booster dose by people who have already taken two doses of Covishield or Covaxin. Last December, the...

iNCOVACC nasal Covid vaccine will cost Rs 800 for private, Rs 325 for govt hospitals

27 Dec 2022

Bharat Biotech's nasal COVID-19 vaccine iNCOVACC, has been approved by the center on Tuesday and at Rs 800 the vaccine will be available in private hospitals and government hospitals, it will be available for Rs 325. In the fourth week of January, the vaccine iNCOVACC will be rolled out. As...